TCGA-78-7540-01A-11R-2066-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.400
- ESTROGEN_RESPONSE_EARLY+0.350
- INTERFERON_ALPHA_RESPONSE+0.330
- ESTROGEN_RESPONSE_LATE+0.320
- PANCREAS_BETA_CELLS+0.320
- TGF_BETA_SIGNALING+0.320
- XENOBIOTIC_METABOLISM+0.300
- COMPLEMENT+0.270
- APICAL_SURFACE+0.260
- NOTCH_SIGNALING+0.230
Top 10 suppressed
- E2F_TARGETS-0.720
- MYC_TARGETS_V2-0.700
- MYC_TARGETS_V1-0.660
- G2M_CHECKPOINT-0.630
- OXIDATIVE_PHOSPHORYLATION-0.440
- MTORC1_SIGNALING-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.380
- DNA_REPAIR-0.330
- MITOTIC_SPINDLE-0.300
- PI3K_AKT_MTOR_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7284-01B-11R-2241-07 | — | cohortA1 | 0.910 |
| 2 | TCGA-69-8254-01A-11R-2287-07 | — | cohortA1 | 0.877 |
| 3 | BS_GYA4V1RD | pilocytic astrocytoma | — | 0.866 |
| 4 | TCGA-50-5935-01A-11R-1755-07 | — | cohortA1 | 0.861 |
| 5 | C3N-03038 | — | cohortA1 | 0.848 |
| 6 | ERR2208890 | — | — | 0.846 |
| 7 | MNG356 | — | — | 0.844 |
| 8 | BS_0WVJYM9R | pilocytic astrocytoma | — | 0.844 |
| 9 | TCGA-64-1681-01A-11R-2066-07 | — | cohortA1 | 0.842 |
| 10 | MNG795 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |